Risk Mitigation For Late-Stage Clinical Assets

By Amy Trotch, Business Development Director/Commercial Technical Transfer, Societal CDMO

Post-pandemic, there is an increasing demand for the CDMO-Biopharma relationship to focus on, dare we say it, “strategic partnering.” Strategic partnering – that industry buzz term used so loosely, with such frequency and abundance, that it edges close to a cliché. Yet, while it is true that the term is often overused and loosely defined when it’s precisely broken down, its basic definition holds the truest of post-pandemic lessons learned.

In today’s unpredictable and challenging times, leveraging the competence and capabilities of the CDMO to bring forth innovative, flexible solutions to safeguard supply chains for their clients and, ultimately, for patients is crucial to strategic partnering. The value-add of a CDMO functioning on this level of partnership, as a trusted and experienced advisor that can provide flexible solutions for late-stage risk mitigation stretches far beyond what is expected in the manufacturing suite.